Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk

By Paul Ainsworth and Michael Bruns ( February 26, 2020, 4:53 PM EST) -- The U.S. Court of Appeals for the Federal Circuit recently affirmed a $70 million jury award for infringement of a manufacturing process patent for a biosimilar product without any infringing sales. The damages award in this case was particularly notable because the patentee did not practice the claimed technology....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!